All news > All
New insulin therapies - big players beware of biotech...
27-Jan-2006 - The big pharma companies may have dreamed of launching the world's first non-injectable insulin, but it has been Canadian biotech company Generex that shattered this dream, bypassing EU and US regulatory processes and launching its inhaled insulin in Ecuador last November. But do biotech companies prove a real threat?
Inhaled insulin delivery - which products will triumph?
25-Jan-2006 - With the first non-injectable insulin to the world market predicted to earn $1.5 bn (€1.2 bn) a year, inhaled pulmonary delivery is winning the race, looking certain to trigger a bitter grapple between the big insulin players.
The insulin market - moving with the times
23-Jan-2006 - Injectable insulin is under threat. The imminent arrival of non-injectable insulin could finally topple the big insulin players off their comfortable perch, in the $7 bn industry that has seen little real competition until now.
The perils of whistleblowing
06-Jan-2006 - The firing of Dr Peter Rost by Pfizer highlights the position that employees can be faced with if they take a stand on what they believe to be illegal activity in the companies they work for.
Spotlight
  ICH sends Q11 guidelines to EU, US & Japanese regulatorsThe ICH has sent its Q11 guidelines on APIs to regulatory bodies in the US, European Union... |
  in-Pharmatechnologist.com's review of Interphex 2012in-Pharmatechnologist.com was at Interphex 2012 in New York, US to launch the revamped version of our website and speak... |
 Effective controls still lacking for continuous processing says Interphex panelContinuous processing is still hamstrung by a lack of control systems and is not ready for specific... |
 BASF buys omega-3 maker Equateq citing pharma potentialBASF has bought omega-3 fatty acid maker Equateq, citing its pharmaceutical and dietary supplements businesses as key... |
 EMA outlines manufacturing quality docs for biologics trialsThe EMA has published final guidelines on manufacturing quality documents needed for biologics entering clinical trials. |